Clinical trials: Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME)
Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema
Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss.
- Trial name
- Macular Edema (NCT07897630)
- Testing
- Bevacizumab
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Khyber Teaching Hospital
Wet Age Related Macular Degeneration, Diabetic Macular Edema
Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study
In this province, optometrists are often responsible for contacting the retinal specialists' office to arrange patients to be examined for suspected emergencies or more routine referrals related to the eye.
- Trial name
- NCT01899963
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- McMaster University
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Diabetic Macular Edema
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
This is an investigator-sponsored trial (IST), an open-label pilot study, assessing the safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.
- Trial name
- NCT00491166
- Testing
- Bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Boston
Diabetes, Diabetic Macular Oedema
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
The specific aim of the study is to test the following hypothesis: That switching between treatments from bevacizumab to Ozurdex or vice versa in eyes with diabetic macular oedema with no or incomplete response from one therapy…
- Conditions
- Diabetes, Diabetic Macular Oedema, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- SwitchDMO (NCT01787669)
- Testing
- Avastin (Bevacizumab), Ozurdex (dexamethasone)
- Where
- 3 sites in Australia
- Volunteers
- 19 people
- Sponsor
- University of Sydney
Diabetic Retinopathy, Diabetic Macular Edema
Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation
This study will compare the side effects of two treatments for diabetic macular edema, in which blood vessels in the retina (tissue that lines the back of the eye) become leaky and the retina and macula (the center part of the…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, DME
- Trial name
- NCT00105404
- Testing
- Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Oedema
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
- Trial name
- NCT06908876
- Testing
- IBI302, Faricimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration, Age-related Macular Degeneration
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related…
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02571972
- Testing
- Dorzolamide-timolol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wills Eye
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Diabetic Macular Edema
Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
This study is designed to assess safety and efficacy of intravitreal injection of Conbercept on visual acuity and anatomic outcomes in patients with diabetic macular edema (DME) .
- Trial name
- NCT02194634
- Testing
- Conbercept, Laser
- Where
- 17 sites in China
- Volunteers
- 248 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetic Macular Edema
Ranibizumab "Treat and Extend" in Diabetic Macular Edma
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to…
- Trial name
- OPTIMAL (NCT01297569)
- Testing
- Ranibizumab
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
This was a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.
- Trial name
- NCT05526729
- Testing
- Beovu
- Where
- 76 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind, parallel active-controlled study.
- Trial name
- NCT05324774
- Testing
- 9MW0813, Aflibercept
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Diabetic Macular Edema
Treatment for CI-DME in Eyes With Very Good VA Study
Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes…
- Trial name
- Protocol V (NCT01909791)
- Testing
- Prompt Laser, Prompt aflibercept, Deferred laser
- Where
- 103 sites in United States, Canada
- Volunteers
- 702 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema, Cataract
Cataract DME - Peri vs. Intraop
Goals of the study are to evaluate how peri-operative versus intra-operative anti-VEGF intravitreous injections affect visual acuity (BCVA) in patients with persistent diabetic macular edema who are undergoing cataract surgery…
- Trial name
- NCT03920878
- Testing
- Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively
- Where
- 2 sites in United States
- Sponsor
- Emory University
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema
This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).
- Trial name
- OPTIMAL-3 (NCT07604545)
- Sponsor
- AbbVie